Skip to content

Clinical trials

Non-alcoholic Fatty Liver Disease trials in Hong Kong

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Non-alcoholic Fatty Liver Disease Country / region: Hong Kong Clear all

38 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20141
20152
20162
20175
20181
20194
20205
20212
20222
20234
20244
20255
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed16
Recruiting10
Terminated6
Active, not recruiting4
Unknown status2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Chinese University of Hong Kong8
The University of Hong Kong6
Gilead Sciences4
Tobira Therapeutics, Inc.3
89bio, Inc.2
GlaxoSmithKline2
Merck Sharp & Dohme LLC2
AstraZeneca1
Boehringer Ingelheim1
Eli Lilly and Company1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Non-alcoholic Fatty Liver Disease38
Fatty Liver9
Fibrosis5
Liver Cirrhosis5
Liver Diseases4
Diabetes Mellitus3
Diabetes Mellitus, Type 23
Metabolic Diseases3
Obesity3
Digestive System Diseases2

Trials

Showing 26 to 38 of 38. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.